Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect.

Fernanda GenreRaquel López-MejíasJavier Rueda-GotorJosé A Miranda-FilloyBegoña UbillaBeatriz Carnero-LópezNatalia Palmou-FontanaInés Gómez-AceboRicardo BlancoTrinitario PinaRodrigo OchoaCarlos González-JuanateyJavier LlorcaMiguel A González-Gay

Published in: Mediators of inflammation (2014)

Elevated TRAIL levels in AS patients may be the result of a compensatory mechanism to reduce CV risk in these patients.

Keyphrases

ankylosing spondylitis
disease activity
rheumatoid arthritis
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
rheumatoid arthritis patients
bone marrow
mesenchymal stem cells